A bipartisan group of 163 lawmakers is urging the Department of Health and Human Services (HHS) to cancel an upcoming pilot ...

Just days and weeks away from key deadlines, the hospital industry’s leading trade organization is still calling for the administration to scrap a one-year pilot of drugmakers’ preferred approach t | ...

Spending through the 340B Drug Pricing Program rose by 565% between 2010 and 2021, increasing from $6.6 billion to $43.9 billion, according to a report from the Congressional Budget Office. In 2021, ...

The hospital lobby wants the Trump administration to investigate Johnson & Johnson, Eli Lilly, Sanofi, Novartis and Bristol ...

The 340B Drug Pricing Program (340B program) is a federal drug discount program that requires drug manufacturers participating in the Medicaid drug rebate program to provide outpatient drugs to ...

Changes to registration requirements for the offsite clinics of 340B-eligible hospitals represent the latest clash between providers, regulators and drugmakers amid the program’s exponential growth.

Despite the rancor, there are many bipartisan opportunities for the divided 118 th Congress. Near the top of the to-do list should be reforming the well-intentioned, but poorly designed, 340B drug ...

Hospitals and small organizations should have equal levels of oversight and scrutiny. One of the critical components for Mainers as they navigate the medical quagmire of insurance, providers and ...

Designed to help hospitals and clinics serving low-income and uninsured patients, the 340B program has evolved into a markup ...